These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 16364578)
1. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Ishida T; Okada Y; Kobayashi T; Kiwada H Int J Pharm; 2006 Feb; 309(1-2):94-100. PubMed ID: 16364578 [TBL] [Abstract][Full Text] [Related]
2. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Evjen TJ; Hagtvet E; Nilssen EA; Brandl M; Fossheim SL Eur J Pharm Sci; 2011 Jul; 43(4):318-24. PubMed ID: 21620968 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Lopes de Menezes DE; Pilarski LM; Allen TM Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662 [TBL] [Abstract][Full Text] [Related]
4. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. Ishida T; Atobe K; Wang X; Kiwada H J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355 [TBL] [Abstract][Full Text] [Related]
6. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Ishida T; Kirchmeier MJ; Moase EH; Zalipsky S; Allen TM Biochim Biophys Acta; 2001 Dec; 1515(2):144-58. PubMed ID: 11718670 [TBL] [Abstract][Full Text] [Related]
7. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468 [TBL] [Abstract][Full Text] [Related]
8. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous active intracellular delivery of doxorubicin and C6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. Fonseca NA; Gomes-da-Silva LC; Moura V; Simões S; Moreira JN J Control Release; 2014 Dec; 196():122-31. PubMed ID: 25305563 [TBL] [Abstract][Full Text] [Related]
11. Ammonium ion level in serum affects doxorubicin release from liposomes. Shibata H; Saito H; Yomota C; Kawanishi T Pharmazie; 2010 Apr; 65(4):251-3. PubMed ID: 20432619 [TBL] [Abstract][Full Text] [Related]
12. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model. Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073 [TBL] [Abstract][Full Text] [Related]
13. A liposomal formulation of doxorubicin, composed of hexadecylphosphocholine (HePC): physicochemical characterization and cytotoxic activity against human cancer cell lines. Papagiannaros A; Hatziantoniou S; Dimas K; Papaioannou GT; Demetzos C Biomed Pharmacother; 2006 Jan; 60(1):36-42. PubMed ID: 16271845 [TBL] [Abstract][Full Text] [Related]
14. [Cationic liposomes loaded with doxorubicin targeting to the tumor neovasculature in vitro]. Zhao W; Ma HL; Qi XR Yao Xue Xue Bao; 2007 Sep; 42(9):982-8. PubMed ID: 18050743 [TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. Cheng WW; Allen TM J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849 [TBL] [Abstract][Full Text] [Related]
16. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Charrois GJ; Allen TM Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619 [TBL] [Abstract][Full Text] [Related]
17. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Allen TM; Mumbengegwi DR; Charrois GJ Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261 [TBL] [Abstract][Full Text] [Related]
18. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy. Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942 [TBL] [Abstract][Full Text] [Related]
19. Correlations between the rate of intracellular release of endocytosed liposomal Doxorubicin and cytotoxicity as determined by a new assay. Kirchmeier MJ; Ishida T; Chevrette J; Allen TM J Liposome Res; 2001; 11(1):15-29. PubMed ID: 19530916 [TBL] [Abstract][Full Text] [Related]
20. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. Pradhan P; Giri J; Rieken F; Koch C; Mykhaylyk O; Döblinger M; Banerjee R; Bahadur D; Plank C J Control Release; 2010 Feb; 142(1):108-21. PubMed ID: 19819275 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]